- Conditions
- Hepatocellular Cancer, Metastatic Liver Cancer
- Interventions
- TACE, Y-90, MWA, IRE
- Procedure
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–117
of 117
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Prostate Cancer
- Interventions
- NanoKnife System, Stereotactic Body Radiation Therapy
- Device · Radiation
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Male only
- Enrollment
- 224 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 8
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Prostate Cancer
- Interventions
- 2mg INO-5150 and electroporation device CELLECTRA®-5P, 8.5mg INO-5150 and electroporation device CELLECTRA®-5P, 2mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P, 8.5mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P, Electroporation using CELLECTRA®-5P
- Biological · Device
- Lead sponsor
- Inovio Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 90 Years · Male only
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 10
- States / cities
- Baltimore, Maryland • Detroit, Michigan • Omaha, Nebraska + 7 more
- Conditions
- Cervical Intraepithelial Neoplasia Grade 2/3, Human Papilloma Virus Infection Type 16
- Interventions
- PVX4 Combination Product, Placebo Control
- Combination Product · Other
- Lead sponsor
- PapiVax Biotech, Inc.
- Other
- Eligibility
- 18 Years to 60 Years · Female only
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Pancreatic Adenocarcinoma
- Interventions
- Nivolumab, Irreversible Electroporation
- Drug · Procedure
- Lead sponsor
- University of Louisville
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2029
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- HIV Infections
- Interventions
- Profectus HIV MAG pDNA vaccine, IL-12, Placebo
- Biological · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Palo Alto, California • San Francisco, California + 8 more
- Conditions
- Prostate Cancer
- Interventions
- Irreversible Electroporation
- Device
- Lead sponsor
- Angiodynamics, Inc.
- Industry
- Eligibility
- 50 Years and older · Male only
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 17
- States / cities
- Orange, California • Aurora, Colorado • Gainesville, Florida + 11 more
- Conditions
- Anal Intraepithelial Neoplasia, High Grade Squamous Intraepithelial Neoplasia, HIV Positivity, Human Papillomavirus-16 Positive, Human Papillomavirus-18 Positive
- Interventions
- Electroporation, HPV DNA Plasmids Therapeutic Vaccine VGX-3100, Laboratory Biomarker Analysis
- Device · Biological · Other
- Lead sponsor
- AIDS Malignancy Consortium
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 7
- States / cities
- San Francisco, California • Atlanta, Georgia • Chicago, Illinois + 4 more
- Conditions
- Urothelial Carcinoma
- Interventions
- INO-5401, INO-9012, Atezolizumab, CELLECTRA® 2000
- Biological · Drug · Device
- Lead sponsor
- Inovio Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Tampa, Florida • Baltimore, Maryland + 7 more
- Conditions
- Healthy
- Interventions
- GLS-5300
- Biological
- Lead sponsor
- GeneOne Life Science, Inc.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Silver Spring, Maryland
- Conditions
- HIV Infections
- Interventions
- HIV-1 nef/tat/vif, env pDNA vaccine, rVSV HIV envC vaccine, Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2019
- U.S. locations
- 2
- States / cities
- Cleveland, Ohio • Philadelphia, Pennsylvania
- Conditions
- Prostate Cancer
- Interventions
- NanoKnife Procedure
- Device
- Lead sponsor
- Angiodynamics, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Rochester, Minnesota
- Conditions
- Triple Negative Breast Cancer
- Interventions
- tavokinogene telseplasmid, Pembrolizumab, Immunopulse, nab paclitaxel, gemcitabine plus carboplatin
- Biological · Device · Drug
- Lead sponsor
- OncoSec Medical Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 10
- States / cities
- Tucson, Arizona • La Jolla, California • Palo Alto, California + 7 more
- Conditions
- HIV-1-infection
- Interventions
- PENNVAX-GP, INO-6145, INO-9012, CELLECTRA® 2000
- Biological · Device
- Lead sponsor
- Steven Deeks
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 2
- States / cities
- Los Angeles, California • San Francisco, California
- Conditions
- HCC
- Interventions
- GNOS-PV02, INO-9012, Pembrolizumab, CELLECTRA®2000 EP Device
- Biological · Drug · Device
- Lead sponsor
- Geneos Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • New York, New York
- Conditions
- Solid Tumor, Adult
- Interventions
- Neoantigen DNA Vaccine, Integrated electroporation device
- Biological · Device
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Hemorrhagic Fever With Renal Syndrome
- Interventions
- Vaccine/device combination for prevention of HFRS
- Biological
- Lead sponsor
- U.S. Army Medical Research and Development Command
- Federal
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Silver Spring, Maryland
- Conditions
- Cervical Intraepithelial Neoplasia
- Interventions
- VGX 3100, Placebo, CELLECTRA™-5P
- Biological · Device
- Lead sponsor
- Inovio Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 55 Years · Female only
- Enrollment
- 167 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 27
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Colton, California + 24 more
- Conditions
- Melanoma (Skin), Intraocular Melanoma
- Interventions
- Xenogeneic Tyrosinase DNA Vaccine, TriGrid Delivery System for Intramuscular Electroporation
- Biological · Device
- Lead sponsor
- Ichor Medical Systems Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Pancreatic Cancer, Locally Advanced Pancreatic Cancer
- Interventions
- Pembrolizumab, Irreversible Electroporation
- Drug · Device
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Cervical Cancer
- Interventions
- INO-3112, CELLECTRA™-5P
- Biological · Device
- Lead sponsor
- Inovio Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Ann Arbor, Michigan • New York, New York